Evidence map›Paper›PMID 38712280›Full record

ArticlebioRxiv : the preprint server for biology2024

Robust prediction of relative binding energies for protein-protein complex mutations using free energy perturbation calculations.

Jared M Sampson, Daniel A Cannon, Jianxin Duan, Jordan C K Epstein, Alina P Sergeeva, Phinikoula S Katsamba, Seetha M Mannepalli, Fabiana A Bahna, Hélène Adihou, Stéphanie M Guéret and 13 more

Abstract readPreprint
In one paragraph

Article in bioRxiv : the preprint server for biology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

23 authors.

Jared M SampsonSchrödinger, Inc., Life Sciences Software, New York, NY, USA.ORCID 0000-0001-6441-1579
Daniel A CannonSchrödinger, GmbH, Life Sciences Software, Mannheim, Germany.ORCID 0000-0002-3497-2559
Jianxin DuanSchrödinger, GmbH, Life Sciences Software, Mannheim, Germany.
Jordan C K EpsteinSchrödinger, Inc., Life Sciences Software, New York, NY, USA.
Alina P SergeevaColumbia University, Department of Systems Biology, New York, NY, USA.ORCID 0000-0002-8886-4123
Phinikoula S KatsambaColumbia University, Zuckerman Mind Brain Behavior Institute, New York, NY, USA, 10027.ORCID 0000-0003-3981-1604
Seetha M MannepalliColumbia University, Zuckerman Mind Brain Behavior Institute, New York, NY, USA, 10027.
Fabiana A BahnaColumbia University, Zuckerman Mind Brain Behavior Institute, New York, NY, USA, 10027.
Hélène AdihouAstraZeneca, Medicinal Chemistry, Research and Early Development, Cardiovascular, Renal and Metabolism, BioPharmaceuticals R&D, Gothenburg, Sweden.ORCID 0000-0003-3005-5259
Stéphanie M GuéretAstraZeneca, Medicinal Chemistry, Research and Early Development, Cardiovascular, Renal and Metabolism, BioPharmaceuticals R&D, Gothenburg, Sweden.ORCID 0000-0001-7220-9506
Ranganath GopalakrishnanAstraZeneca, Medicinal Chemistry, Research and Early Development, Cardiovascular, Renal and Metabolism, BioPharmaceuticals R&D, Gothenburg, Sweden.ORCID 0000-0001-9825-2334
Stefan GeschwindnerAstraZeneca, Mechanistic and Structural Biology, Discovery Sciences, R&D, Cambridge, UK.ORCID 0000-0002-2154-8345
D Gareth ReesAstraZeneca, Biologics Engineering, R&D, Cambridge, UK.ORCID 0000-0002-4268-6018
Anna SigurdardottirAstraZeneca, Biologics Engineering, R&D, Cambridge, UK.ORCID 0000-0002-5225-397X
Trevor WilkinsonAstraZeneca, Biologics Engineering, R&D, Cambridge, UK.ORCID 0009-0008-0806-366X
Roger B DoddAstraZeneca, Biologics Engineering, R&D, Cambridge, UK.ORCID 0000-0003-4268-1863
Leonardo De MariaAstraZeneca, Medicinal Chemistry, Research and Early Development, Respiratory and Immunology, BioPharmaceuticals R&D, Gothenburg, Sweden.ORCID 0000-0002-8061-4242
Juan Carlos MobarecAstraZeneca, Mechanistic and Structural Biology, Discovery Sciences, R&D, Cambridge, UK.ORCID 0000-0001-9482-4294
Lawrence ShapiroColumbia University, Zuckerman Mind Brain Behavior Institute, New York, NY, USA, 10027.ORCID 0000-0001-9943-8819
Barry HonigColumbia University, Department of Systems Biology, New York, NY, USA.ORCID 0000-0002-1835-1031
Andrew BuchananAstraZeneca, Biologics Engineering, R&D, Cambridge, UK.ORCID 0000-0002-5191-7682
Richard A FriesnerColumbia University, Department of Chemistry, New York, NY, USA.ORCID 0000-0002-1708-9342
Lingle WangSchrödinger, Inc., Life Sciences Software, New York, NY, USA.ORCID 0000-0002-8170-6798

Funding

Genome-wide structure-based analysis of protein-protein interactions and networksR35GM139585 · NIGMS · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI BARRY H HONIG · 2021 to 2026
$2.7M
NIGMS NIH HHS R35 GM139585
6 · The paper itself

Abstract

Computational free energy-based methods have the potential to significantly improve throughput and decrease costs of protein design efforts. Such methods must reach a high level of reliability, accuracy, and automation to be effectively deployed in practical industrial settings in a way that impacts protein design projects. Here, we present a benchmark study for the calculation of relative changes in protein-protein binding affinity for single point mutations across a variety of systems from the literature, using free energy perturbation (FEP+) calculations. We describe a method for robust treatment of alternate protonation states for titratable amino acids, which yields improved correlation with and reduced error compared to experimental binding free energies. Following careful analysis of the largest outlier cases in our dataset, we assess limitations of the default FEP+ protocols and introduce an automated script which identifies probable outlier cases that may require additional scrutiny and calculates an empirical correction for a subset of charge-related outliers. Through a series of three additional case study systems, we discuss how protein FEP+ can be applied to real-world protein design projects, and suggest areas of further study.

Indexed as

Binding affinity predicitonFree energy methodsIn silico mutational screeningProtein binding interface optimizationProtein-protein interactions

Identifiers

PMID38712280
PMCPMC11071377

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.